Immune-based combinations for metastatic triple negative breast cancer in clinical trials: current knowledge and therapeutic prospects

References

• Bergin ART, Loi S. Triple-negative breast cancer: recent treatment advances. F1000Res. 2019Aug2;8:F1000Faculty Rev–1342. PMID: 31448088; PMCID: PMC6681627.
   Google Scholar
• Kumar P, Aggarwal R. An overview of triple-negative breast cancer. Arch Gynecol Obstet. 2016Feb;293(2):247–269. Epub 2015 Sep 4. PMID: 26341644.
   PubMed Web of Science ®Google Scholar
• Keenan TE, Tolaney SM. Role of immunotherapy in triple-negative breast cancer. J Natl Compr Canc Netw. 2020Apr;18(4):479–489. PMID: 32259782.
   PubMed Web of Science ®Google Scholar
• Marra A, Viale G, Curigliano G. Recent advances in triple negative breast cancer: the immunotherapy era. BMC Med. 2019May9;17(1):90. PMID: 31068190; PMCID: PMC6507064.
   PubMed Web of Science ®Google Scholar
• Jia H, Truica CI, Wang B, et al. Immunotherapy for triple-negative breast cancer: existing challenges and exciting prospects. Drug Resist Updat. 2017May;32:1–15. Epub 2017 Aug 19. PMID: 29145974.
   PubMed Web of Science ®Google Scholar
• Emens LA. Breast cancer immunotherapy: facts and hopes. Clin Cancer Res. 2018Feb1;24(3):511–520. Epub 2017 Aug 11. PMID: 28801472; PMCID: PMC5796849.
   PubMed Web of Science ®Google Scholar
• Sporikova Z, Koudelakova V, Trojanec R, et al. Genetic markers in triple-negative breast cancer. Clin Breast Cancer. 2018Oct;18(5):e841–e850. Epub 2018 Aug 4. PMID: 30146351.
   PubMed Web of Science ®Google Scholar
• Yin L, Duan JJ, Bian XW, et al. Triple-negative breast cancer molecular subtyping and treatment progress. Breast Cancer Res. 2020Jun9;22(1):61. PMID: 32517735; PMCID: PMC7285581.
   PubMed Web of Science ®Google Scholar
• Adams S, Loi S, Toppmeyer D, et al. Pembrolizumab monotherapy for previously untreated, PD-L1-positive, metastatic triple-negative breast cancer: cohort B of the phase II KEYNOTE-086 study. Ann Oncol. 2019Mar1;30(3):405–411. PMID: 30475947.
   PubMed Web of Science ®Google Scholar
• Winer EP, Lipatov O, Im SA, et al. KEYNOTE-119 investigators. Pembrolizumab versus investigator-choice chemotherapy for metastatic triple-negative breast cancer (KEYNOTE-119): a randomised, open-label, phase 3 trial. Lancet Oncol. 2021Apr4;22(4):499–511. Epub 2021 Mar 4. PMID: 33676601.
   PubMed Web of Science ®Google Scholar
• Emens LA, Cruz C, Eder JP, et al. Long-term clinical outcomes and biomarker analyses of atezolizumab therapy for patients with metastatic triple-negative breast cancer: a phase 1 study. JAMA Oncol. 2019Jan1;5(1):74–82. PMID: 30242306; PMCID: PMC6439773.
   PubMed Web of Science ®Google Scholar
• Reddy SM, Carroll E, Nanda R. Atezolizumab for the treatment of breast cancer. Expert Rev Anticancer Ther. 2020Mar;20(3):151–158. Epub 2020 Feb 27. PMID: 32067545.
   PubMed Web of Science ®Google Scholar
• Lyons TG. Targeted therapies for triple-negative breast cancer. Curr Treat Options Oncol. 2019Nov21;20(11):82. PMID: 31754897.
   PubMed Web of Science ®Google Scholar
• Bianchini G, Balko JM, Mayer IA, et al. Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease. Nat Rev Clin Oncol. 2016Nov;13(11):674–690. Epub 2016 May 17. PMID: 27184417; PMCID: PMC5461122.
   PubMed Web of Science ®Google Scholar
• Kwapisz D. Pembrolizumab and atezolizumab in triple-negative breast cancer. Cancer Immunol Immunother. 2021Mar;70(3):607–617. Epub 2020 Oct 5. PMID: 33015734.
   PubMed Web of Science ®Google Scholar
• Rizzo A, Ricci AD, Brandi G. Immune-based combinations for advanced hepatocellular carcinoma: shaping the direction of first-line therapy. Future Oncol. 2021Mar;17(7):755–757. Epub 2021 Jan 29. PMID: 33508960.
   PubMed Web of Science ®Google Scholar
• Da Silva JL, Cardoso Nunes NC, Izetti P, et al. Triple negative breast cancer: a thorough review of biomarkers. Crit Rev Oncol Hematol. 2020Jan;145:102855. Epub 2019 Dec 20. PMID: 31927455.
   PubMed Web of Science ®Google Scholar
• Sugie T. Immunotherapy for metastatic breast cancer. Chin Clin Oncol. 2018Jun7;7(3):28. PMID: 30056730.
   PubMed Web of Science ®Google Scholar
• Al-Mahmood S, Sapiezynski J, Garbuzenko OB, et al. Metastatic and triple-negative breast cancer: challenges and treatment options. Drug Deliv Transl Res. 2018Oct8;8(5):1483–1507. PMID: 29978332; PMCID: PMC6133085.
   PubMed Web of Science ®Google Scholar
• Vikas P, Borcherding N, Zhang W. The clinical promise of immunotherapy in triple-negative breast cancer. Cancer Manag Res. 2018Dec10;10:6823–6833. PMID: 30573992; PMCID: PMC6292225.
   PubMed Web of Science ®Google Scholar
• Iams WT, Porter J, Horn L. Immunotherapeutic approaches for small-cell lung cancer. Nat Rev Clin Oncol. 2020May;17(5):300–312. Epub 2020 Feb 13. PMID: 32055013; PMCID: PMC7212527.
   PubMed Web of Science ®Google Scholar
• Zheng H, Zeltsman M, Zauderer MG, et al. Chemotherapy-induced immunomodulation in non-small-cell lung cancer: a rationale for combination chemoimmunotherapy. Immunotherapy. 2017Sep9;9(11):913–927. PMID: 29338609; PMCID: PMC5810850.
   PubMed Web of Science ®Google Scholar
• Ghiringhelli F, Menard C, Puig PE, et al. Metronomic cyclophosphamide regimen selectively depletes CD4+CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patients. Cancer Immunol Immunother. 2007May;56(5):641–648. Epub 2006 Sep 8. PMID: 16960692.
   PubMed Web of Science ®Google Scholar
• Kwa M, Li X, Novik Y, et al. Serial immunological parameters in a phase II trial of exemestane and low-dose oral cyclophosphamide in advanced hormone receptor-positive breast cancer. Breast Cancer Res Treat. 2018Feb;168(1):57–67. Epub 2017 Nov 9. PMID: 29124456.
   PubMed Web of Science ®Google Scholar
• Kroemer G, Galluzzi L, Kepp O, et al. Immunogenic cell death in cancer therapy. Annu Rev Immunol. 2013;31(1):51–72. Epub 2012 Nov 12. PMID: 23157435.
   PubMed Web of Science ®Google Scholar
• Garg AD, Dudek-Peric AM, Romano E, et al. Immunogenic cell death. Int J Dev Biol. 2015;59(1–2–3):131–140. PMID: 26374534.
   PubMed Web of Science ®Google Scholar
• Krasniqi E, Barchiesi G, Pizzuti L, et al. Immunotherapy in HER2-positive breast cancer: state of the art and future perspectives. J Hematol Oncol. 2019Oct29;12(1):111. PMID: 31665051; PMCID: PMC6820969.
   PubMed Web of Science ®Google Scholar
• Gandhi L, Rodríguez-Abreu D, Gadgeel S, et al. KEYNOTE-189 investigators. pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer. N Engl J Med. 2018May31;378(22):2078–2092. Epub 2018 Apr 16. PMID: 29658856.
   PubMed Web of Science ®Google Scholar
• Paz-Ares L, Luft A, Vicente D, et al. KEYNOTE-407 investigators. pembrolizumab plus chemotherapy for squamous non-small-cell lung cancer. N Engl J Med. 2018Nov22;379(21):2040–2051. Epub 2018 Sep 25. PMID: 30280635.
   PubMed Web of Science ®Google Scholar
• Paz-Ares L, Dvorkin M, Chen Y, et al. CASPIAN investigators. Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial. Lancet. 2019Nov23;394(10212):1929–1939. Epub 2019 Oct 4. PMID: 31590988.
   PubMed Web of Science ®Google Scholar
• Ricci AD, Rizzo A, Brandi G. Immunotherapy in biliary tract cancer: worthy of a second look. Cancer Control. 2020Jul-Aug;27(3):1073274820948047. PMID: 32806956; PMCID: PMC7791443.
   Web of Science ®Google Scholar
• Schmid P, Rugo HS, Adams S, et al. IMpassion130 Investigators. Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2020Jan;21(1):44–59. Epub 2019 Nov 27. PMID: 31786121.
   PubMed Web of Science ®Google Scholar
• Miles D, Gligorov J, André F, et al. IMpassion131 investigators. Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer. Ann Oncol. 2021Aug;32(8):994–1004. Epub 2021 Jul 1. PMID: 34219000.
   PubMed Web of Science ®Google Scholar
• Cortes J, Cescon DW, Rugo HS, et al. KEYNOTE-355 Investigators. Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial. Lancet. 2020Dec5;396(10265):1817–1828. PMID: 33278935.
   PubMed Web of Science ®Google Scholar
• Basu A, Ramamoorthi G, Jia Y, et al. Immunotherapy in breast cancer: current status and future directions. Adv Cancer Res. 2019;143:295–349. Epub 2019 May 2. PMID: 31202361.
   PubMed Web of Science ®Google Scholar
• de Melo Gagliato D, Buzaid AC, Perez-Garcia J, et al. Immunotherapy in breast cancer: current practice and clinical challenges. BioDrugs. 2020Oct;34(5):611–623. PMID: 32870473.
   PubMed Web of Science ®Google Scholar
• Tolaney SM, Kalinsky K, Kaklamani VG, et al. Eribulin plus pembrolizumab in patients with metastatic triple-negative breast cancer (ENHANCE 1): a Phase Ib/II Study. Clin Cancer Res. 2021 Jun 1;27(11):3061–3068. Epub 2021 Mar 16. PMID: 33727258.
   PubMed Web of Science ®Google Scholar
• Ricci AD, Rizzo A, Brandi G. The DNA damage repair (DDR) pathway in biliary tract cancer (BTC): a new Pandora’s box? ESMO Open. 2020Sep;5(5):e001042. PMID: 32994319; PMCID: PMC7526276.
   PubMed Web of Science ®Google Scholar
• Sen T, Rodriguez BL, Chen L, et al. Targeting DNA damage response promotes antitumor immunity through STING-Mediated T-cell activation in small cell lung cancer. Cancer Discov. 2019May9;9(5):646–661. Epub 2019 Feb 18. PMID: 30777870; PMCID: PMC6563834.
   PubMed Web of Science ®Google Scholar
• Pilié PG, Gay CM, Byers LA, et al. PARP Inhibitors: extending Benefit Beyond BRCA-Mutant Cancers. Clin Cancer Res. 2019Jul1;25(13):3759–3771. Epub 2019 Feb 13. PMID: 30760478.
   PubMed Web of Science ®Google Scholar
• Zhu H, Wei M, Xu J, et al. PARP inhibitors in pancreatic cancer: molecular mechanisms and clinical applications. Mol Cancer. 2020Mar2;19(1):49. PMID: 32122376; PMCID: PMC7053129.
   PubMed Web of Science ®Google Scholar
• Mizrahi JD, Surana R, Valle JW, et al. Pancreatic cancer. Lancet. 2020Jun27;395(10242):2008–2020. PMID: 32593337.
   PubMed Web of Science ®Google Scholar
• Brown JS, O’Carrigan B, Jackson SP, et al. Targeting DNA Repair in Cancer: beyond PARP Inhibitors. Cancer Discov. 2017Jan7;7(1):20–37. Epub 2016 Dec 21. PMID: 28003236; PMCID: PMC5300099.
   PubMed Web of Science ®Google Scholar
• Turk AA, Wisinski KB. PARP inhibitors in breast cancer: bringing synthetic lethality to the bedside. Cancer. 2018Jun15;124(12):2498–2506. Epub 2018 Apr 16. PMID: 29660759; PMCID: PMC5990439.
   PubMed Web of Science ®Google Scholar
• Boussios S, Karihtala P, Moschetta M, et al. Combined Strategies with Poly (ADP-Ribose) Polymerase (PARP) Inhibitors for the Treatment of Ovarian Cancer: a Literature Review. Diagnostics (Basel). 2019Aug1;9(3):87. PMID: 31374917; PMCID: PMC6787707.
   Google Scholar
• Sachdev E, Tabatabai R, Roy V, et al. PARP inhibition in cancer: an update on clinical development. Target Oncol. 2019Dec;14(6):657–679. PMID: 31625002.
   PubMed Web of Science ®Google Scholar
• Vikas P, Borcherding N, Chennamadhavuni A, et al. Therapeutic Potential of Combining PARP inhibitor and immunotherapy in solid tumors. Front Oncol. 2020Apr28;10:570. PMID: 32457830; PMCID: PMC7228136.
   PubMed Web of Science ®Google Scholar
• Esteva FJ, Hubbard-Lucey VM, Tang J, et al. Immunotherapy and targeted therapy combinations in metastatic breast cancer. Lancet Oncol. 2019Mar;20(3):e175–e186. PMID: 30842061.
   PubMed Web of Science ®Google Scholar
• Vinayak S, Tolaney SM, Schwartzberg L, et al. Open-label clinical trial of niraparib combined with pembrolizumab for treatment of advanced or metastatic triple-negative breast cancer. JAMA Oncol. 2019Aug1;5(8):1132–1140. PMID: 31194225; PMCID: PMC6567845.
   PubMed Web of Science ®Google Scholar
• Domchek SM, Postel-Vinay S, Im SA, et al. Olaparib and durvalumab in patients with germline BRCA-mutated metastatic breast cancer (MEDIOLA): an open-label, multicentre, phase 1/2, basket study. Lancet Oncol. 2020Sep;21(9):1155–1164. Epub 2020 Aug 6. PMID: 32771088.
   PubMed Web of Science ®Google Scholar
• McGuinness JE, Kalinsky K. Antibody-drug conjugates in metastatic triple negative breast cancer: a spotlight on sacituzumab govitecan, ladiratuzumab vedotin, and trastuzumab deruxtecan. Expert Opin Biol Ther. 2021Jul;21(7):903–913. Epub 2020 Dec 27. PMID: 33089726.
   PubMed Web of Science ®Google Scholar
• Zangardi ML, Spring LM, Nagayama A, et al. Sacituzumab for the treatment of triple-negative breast cancer: the poster child of future therapy? Expert Opin Investig Drugs. 2019Feb;28(2):107–112. Epub 2018 Dec 17. PMID: 30507322.
   PubMed Web of Science ®Google Scholar
• Nagayama A, Vidula N, Ellisen L, et al. Novel antibody-drug conjugates for triple negative breast cancer. Ther Adv Med Oncol. 2020May11;12:1758835920915980. PMID: 32426047; PMCID: PMC7222243.
   Web of Science ®Google Scholar
• Abbas AJ, Ibrahim MF, Saifo MS. Antibody-Drug Conjugates Used in Breast Cancers. J Oncol. 2021Jun24;2021:9927433. PMID: 34257655; PMCID: PMC8257388.
   PubMed Web of Science ®Google Scholar
• É C, Mesquita A. Emerging therapeutic drugs in metastatic triple-negative breast cancer. Breast Cancer (Auckl). 2021Mar22;15:11782234211002491. PMID: 33814914; PMCID: PMC7989121.
   Web of Science ®Google Scholar
• Nagayama A, Vidula N, Bardia A. Novel Therapies for Metastatic Triple-Negative Breast Cancer: spotlight on Immunotherapy and Antibody-Drug Conjugates. Oncology (Williston Park). 2021May13;35(3505):249–254. PMID: 33983696.
   PubMedGoogle Scholar
• Adams E, Wildiers H, Neven P, et al. Sacituzumab govitecan and trastuzumab deruxtecan: two new antibody-drug conjugates in the breast cancer treatment landscape. ESMO Open. 2021Jul2;6(4):100204. Epub ahead of print. PMID: 34225076; PMCID: PMC8259232.
   PubMed Web of Science ®Google Scholar
• Spring LM, Nakajima E, Hutchinson J, et al. Sacituzumab govitecan for metastatic triple-negative breast cancer: clinical overview and management of potential toxicities. Oncologist. 2021Jun27;26(10):827–834. Epub ahead of print. PMID: 34176192.
   PubMed Web of Science ®Google Scholar
• Bardia A, Sa H, Sm T, et al. ASCENT clinical trial investigators. sacituzumab govitecan in metastatic triple-negative breast cancer. N Engl J Med. 2021Apr22;384(16):1529–1541. PMID: 33882206.
   PubMed Web of Science ®Google Scholar
• Mahtani R, Kittaneh M, Kalinsky K, et al. Breast Cancer Therapy Expert Group (BCTEG). advances in therapeutic approaches for triple-negative breast cancer. Clin Breast Cancer. 2020Dec29;S1526-8209(20)30339–6. Epub ahead of print. PMID: 33781662 https://doi.org/10.1016/j.clbc.2020.12.011
   Google Scholar
• Bartsch R. ESMO 2020: highlights in breast cancer. Memo. 2021Apr30;1–4. Epub ahead of print. PMID: 33968263; PMCID: PMC8090520 https://doi.org/10.1007/s12254-021-00713-5
   Google Scholar
• Young JA, Tan AR. Targeted treatment of triple-negative breast cancer. Cancer J. 2021Jan-Feb01;27(1):50–58. PMID: 33475293.
   PubMed Web of Science ®Google Scholar
• Frankel T, Lanfranca MP, Zou W. The role of tumor microenvironment in cancer immunotherapy. Adv Exp Med Biol. 2017;1036:51–64. PMID: 29275464.
   PubMed Web of Science ®Google Scholar
• Bader JE, Voss K, Rathmell JC. Targeting metabolism to improve the tumor microenvironment for cancer immunotherapy. Mol Cell. 2020Jun18;78(6):1019–1033. PMID: 32559423; PMCID: PMC7339967.
   PubMed Web of Science ®Google Scholar
• Chauvin JM, Zarour HM. TIGIT in cancer immunotherapy. J Immunother Cancer. 2020Sep8;8(2):e000957. PMID: 32900861; PMCID: PMC7477968.
   PubMed Web of Science ®Google Scholar
• Dougall WC, Kurtulus S, Smyth MJ, et al. TIGIT and CD96: new checkpoint receptor targets for cancer immunotherapy. Immunol Rev. 2017Mar;276(1):112–120. PMID: 28258695.
   PubMed Web of Science ®Google Scholar
• Goliwas KF, Deshane JS, Elmets CA, et al. Moving Immune Therapy Forward Targeting TME. Physiol Rev. 2021Apr1;101(2):417–425. Epub 2020 Aug 13. PMID: 32790578; PMCID: PMC8428923.
   PubMed Web of Science ®Google Scholar
• Pitt JM, Marabelle A, Eggermont A, et al. Targeting the tumor microenvironment: removing obstruction to anticancer immune responses and immunotherapy. Ann Oncol. 2016Aug;27(8):1482–1492. Epub 2016 Apr 10. PMID: 27069014.
   PubMed Web of Science ®Google Scholar
• Yoo C, Oh DY, Choi HJ, et al. Phase I study of bintrafusp alfa, a bifunctional fusion protein targeting TGF-β and PD-L1, in patients with pretreated biliary tract cancer. J Immunother Cancer. 2020May;8(1):e000564. PMID: 32461347; PMCID: PMC7254161.
   PubMed Web of Science ®Google Scholar
• Paz-Ares L, Kim TM, Vicente D, et al. Bintrafusp Alfa, a Bifunctional Fusion Protein Targeting TGF-β and PD-L1, in Second-Line Treatment of Patients With NSCLC: results From an Expansion Cohort of a Phase 1 Trial. J Thorac Oncol. 2020Jul;15(7):1210–1222. Epub 2020 Mar 13. PMID: 32173464; PMCID: PMC8210474.
   PubMed Web of Science ®Google Scholar
• Rizzo A, Ricci AD, Brandi G. Durvalumab: an investigational anti-PD-L1 antibody for the treatment of biliary tract cancer. Expert Opin Investig Drugs. 2021Apr;30(4):343–350. Epub 2021 Mar 9. PMID: 33645367.
   PubMed Web of Science ®Google Scholar
• Cho BC, Daste A, Ravaud A, et al. Bintrafusp alfa, a bifunctional fusion protein targeting TGF-β and PD-L1, in advanced squamous cell carcinoma of the head and neck: results from a phase I cohort. J Immunother Cancer. 2020Jul;8(2):e000664. Erratum in: J Immunother Cancer. 2020 Oct;8(2): PMID: 32641320; PMCID: PMC7342865.
   PubMed Web of Science ®Google Scholar
• Teicher BA. TGFβ-Directed Therapeutics: 2020. Pharmacol Ther. 2021Jan;217:107666. Epub 2020 Aug 21. PMID: 32835827; PMCID: PMC7770020.
   PubMed Web of Science ®Google Scholar
• Rizzo A, Ricci AD, Brandi G. Atezolizumab in advanced hepatocellular carcinoma: good things come to those who wait. Immunotherapy. 2021Jun;13(8):637–644. Epub 2021 Apr 6. PMID: 33820447.
   PubMed Web of Science ®Google Scholar
• Kim BG, Malek E, Choi SH, et al. Novel therapies emerging in oncology to target the TGF-β pathway. J Hematol Oncol. 2021Apr6;14(1):55. PMID: 33823905; PMCID: PMC8022551.
   PubMed Web of Science ®Google Scholar
• Ozawa Y, Hicks KC, Minnar CM, et al. Analysis of the tumor microenvironment and anti-tumor efficacy of subcutaneous vs systemic delivery of the bifunctional agent bintrafusp alfa. Oncoimmunology. 2021May3;10(1):1915561. PMID: 33996267; PMCID: PMC8096334.
   PubMed Web of Science ®Google Scholar
• Schwarm FP, Uhle F, Schänzer A, et al. High-mobility group AT-hook protein 2 expression and its prognostic significance in MGMT methylated and unmethylated glioblastoma. Int J Oncol. 2016Apr;48(4):1485–1492. Epub 2016 Feb 17. PMID: 26892260.
   PubMed Web of Science ®Google Scholar
• Liu Y, Li X, Zhang Y, et al. An miR-340-5p-macrophage feedback loop modulates the progression and tumor microenvironment of glioblastoma multiforme. Oncogene. 2019Dec;38(49):7399–7415. Epub 2019 Aug 19. PMID: 31427735.
   PubMed Web of Science ®Google Scholar
• Goel S, DeCristo MJ, Watt AC, et al. CDK4/6 inhibition triggers anti-tumour immunity. Nature. 2017Aug24;548(7668):471–475. Epub 2017 Aug 16. PMID: 28813415; PMCID: PMC5570667.
   PubMed Web of Science ®Google Scholar
• Goel S, DeCristo MJ, McAllister SS, et al. CDK4/6 inhibition in cancer: beyond cell cycle arrest. Trends Cell Biol. 2018Nov;28(11):911–925. Epub 2018 Jul 27. PMID: 30061045; PMCID: PMC6689321.
   PubMed Web of Science ®Google Scholar
• Deng J, Wang ES, Jenkins RW, et al. CDK4/6 Inhibition Augments Antitumor Immunity by Enhancing T-cell Activation. Cancer Discov. 2018Feb8;8(2):216–233. Epub 2017 Nov 3. PMID: 29101163; PMCID: PMC5809273.
   PubMed Web of Science ®Google Scholar
• Álvarez-Fernández M, Malumbres M. Mechanisms of Sensitivity and Resistance to CDK4/6 Inhibition. Cancer Cell. 2020Apr13;37(4):514–529. PMID: 32289274.
   PubMed Web of Science ®Google Scholar
• Murphy CG. The Role of CDK4/6 Inhibitors in Breast Cancer. Curr Treat Options Oncol. 2019May18;20(6):52. PMID: 31101994.
   PubMed Web of Science ®Google Scholar
• Tolaney SM, Kabos P, Dickler MN, et al. Updated efficacy, safety, & PD-L1 status of patients with HR+, HER2- metastatic breast cancer administered abemaciclib plus pembrolizumab. ASCO Annual Meeting 2018. J clin oncol. 2018;36(15_suppl):abstract 1059.
   Web of Science ®Google Scholar
• Brufsky A, Kim SB, Zvirbule Z, et al. A phase II randomized trial of cobimetinib plus chemother- apy, with or without atezolizumab, as first-line treatment for pa- tients with locally advanced or metastatic triple-negative breast can- cer (COLET): primary analysis. Ann Oncol. 2021;32(5):652–660.
   PubMed Web of Science ®Google Scholar
• Schmid P, Loirat D, Savas P, et al. Phase Ib study evaluating a triplet combination of ipatasertib (IPAT), atezolizumab (atezo), and paclitaxel (PAC) or nab-PAC as first-line (1L) therapy for locally advanced/metastatic triple-negative breast cancer (TNBC). AACR annual meeting 2019. Cancer Res. 2019;79(suppl_13):abstract CT049.
   Web of Science ®Google Scholar
• Rizzo A, Dadduzio V, Ricci AD, et al. Lenvatinib plus pembrolizumab: the next frontier for the treatment of hepatocellular carcinoma? Expert Opin Investig Drugs. 2021Jun30;1–8. Epub ahead of print. PMID: 34167433 https://doi.org/10.1080/13543784.2021.1948532
   Web of Science ®Google Scholar
• Rizzo A, Ricci AD. PD-L1, TMB, and other potential predictors of response to immunotherapy for hepatocellular carcinoma: how can they assist drug clinical trials? Expert Opin Investig Drugs. 2021Aug30;1–9. Epub ahead of print. PMID: 34429006 https://doi.org/10.1080/13543784.2021.1972969
   Google Scholar